Evaluation of the efficacy of transdermal administration of maropitant in managing vomiting in cats

Youcef Boukaache*, Marie-Laurence Ferret, Valérie Delteil-Prévotat, Karim Khoukh, Andra Enache, Dorothée Iwaszikiw, Sébastien Bertin, and Fabien Bruno

Delpech Pharmacy, Paris, France

Abstract

Background: Antiemetic maropitant is a widely used medication for treating acute and chronic vomiting in cats. It is available as tablets or injectable solution (Cerenia®). With the oral and injectable routes being especially difficult to pursue in cats experiencing vomiting and nausea, the transdermal administration might be an efficient alternative. The aim of this study was to demonstrate the antiemetic effect of maropitant administered via the transdermal route in cats. Case Description: There were 8 cats enrolled in this study, weighing between 2 and 7 kg, more than 6 months old, and experiencing at least 2 episodes of vomiting in the last 72 hours. Compounded transdermal maropitant was prepared using finely ground Cerenia® tablets, dissolved in propylene glycol and incorporated in the commercial liposomal base Pentravan® (Fagron®, Thiais, France). The uniformity of content was determined using the high performance liquid chromatography (HPLC) method. The product was administered at a dosage of 4 mg/cat once a day (QD), applied on the inner pinna of the ear for five consecutive days. Monitoring and evaluation of vomiting frequency and nausea were performed. A significant decrease in vomiting frequency was observed in 6 of the 8 enrolled cats. A reduction in nausea, associated with an improvement of appetite, was observed in some cases.

Conclusion: Transdermal application of maropitant to cats experiencing vomiting seems to be efficient and a good alternative to existing oral medication, taking into account the difficulty of oral administration in these cases. This work provides preliminary clinical results of the efficacy of transdermal maropitant in cats. Further studies are necessary to determine dosing and pharmacokinetics.

Keywords: Cat, Compounding, Maropitant, Transdermal, Vomiting.
ease of administration by the owner and its noninvasive character for the animal.

**Case Details**
This study was carried out on eight cats. The inclusion criteria were the age of more than 6 months and 2 episodes of vomiting in the 72 hours prior to the transdermal treatment. The selected candidates were cats weighing between 2 and 7 kg, with the mean age of 11.45 years, with a range from 7 months to 19 years. There were five male cats and three female cats.

The animals selected for the study were cats received at the veterinary clinics for vomiting related to different pathologies (most often pancreatitis). The compounded transdermal maropitant was made using tablets of Cerenia® finely ground into powder, which was dissolved in propylene glycol and then incorporated into the commercial liposomal base Pentraván® (Fagron®, Thiais, France). The formulation was made by the same compounding pharmacy, under the same conditions of manufacture. The uniformity of the content of the compounded formula was determined using an in-house high performance liquid chromatography (HPLC) method, validated according to the ICH guidelines Q2(R1) for linearity, specificity, accuracy, precision, robustness, and limit of detection / limit of quantification (LOD/LOQ).

The transdermal pen (MD® PEN, Medisca®) is a device that comprises a cartridge filled with the cream, which is inserted in a tube that represents the body of the pen. The base of the device must be pressed to deliver the cream through a silicone tip. The device contains 6.5 ml of cream and delivers precise and repeatable doses of 0.1 ml for every pressing of the base. The starting dose used for the transdermal application has been chosen based on the usual oral dose of 1 mg/kg (Hickman et al., 2008). We calculated a median dose of 4 mg/cat to standardize the manufacturing process and the stability conditions of the preparation.

The owner or the veterinarian had to administer on the inner pinna of the ear a dose of transdermal cream at 4 mg/cat (concentration of 4 mg/0.1 ml) daily for five consecutive days. The number of vomiting was then quantified by the owner or the veterinarian from day 1 to day 5. Any side effects or additional treatments or tests were also notified.

The results show a decrease of 63% in the number of vomiting during the administration of the maropitant transdermal preparation for five consecutive days, as well as a noticeable improvement in appetite.

The evolution of vomiting from day -3 to day 5 for the eight cats is detailed in Figure 1.

The first cat (Cat 1; Fig. 1) treated with transdermal maropitant experienced two vomiting 72 hours prior to the treatment, continued with one vomiting per day the first 2 days and then the vomiting stopped. Four of the eight cats (Cat 3, Cat 4, Cat 5, and Cat 7; Fig. 1) passed from 13, 7, 5 and 3, respectively, to zero vomiting from day 1 of the maropitant transdermal treatment; another one of the cats (Cat 2; Fig. 1) passed from 6 vomiting in the 72 hours prior to the initiation of maropitant to 1 vomiting per day for the 5 days of the trial. One of the cats (Cat 6; Fig. 1) enrolled passed from 15 episodes of vomiting in the 72 hours prior to the administration of maropitant to 0 vomiting per day in the first 2 days of the treatment; after experiencing 7 vomiting on the third day, the veterinarian decided to increase the dose to 2 applications (one application every 12 hours) and the vomiting episodes decreased to zero per day for the next 2 days.

The administration of transdermal maropitant proved no efficacy for one 19-year-old cat (Cat 8; Fig. 1) that experienced 7 vomiting prior to the administration of maropitant and continued with 2 vomiting per day on days 1 and 4 and 1 vomiting per day on days 2 and 3 of the treatment. The cat was reportedly suffering from chronic kidney failure.

**Discussion**
Chronic vomiting in cats is one of the most common health concerns experienced by owners nowadays (Sorrell, 2021). In this cases, the oral or injectable routes can prove to be difficult to accomplish, therefore, the transdermal administration appears to be a more easy and suitable solution (Davidson, 2003).

This is the first case report studying the efficacy of the transdermal administration of maropitant against vomiting in cats.

The transdermal application of maropitant at a dose comparable to the oral dose (4 mg/cat) for five consecutive days resulted in a reduction of vomiting in six of the eight cats included in this report. There were no adverse effects reported for the transdermal administration, which is similar to the studies for the oral route for maropitant (Quimby et al., 2015).

The influence of the appetite was subjectively evaluated by the owner and was not objectively quantified; therefore, there are no exact results to show in this study. However, this point could be developed in a future study similarly to the case of mirtazapine (Poole et al., 2019), where the participants could be weighted after the treatment. The amount of the ingested food could be also quantified. In our study, half of the owners found that the appetite increased back to normal after the treatment.

This study did not attempt to assess the influence of the adjacent pathologies or physiological state of the animal on the efficacy of transdermal maropitant. Further diagnosis may be needed in cases of chronic vomiting, even though the symptoms can be intermittent. In such cases, the underlying cause must be determined. The therapeutic approach for a cat with chronic vomiting should then be developed based on identified etiology (Hauck et al., 2016).

Being a quick-acting, noninvasive, easy to use device and a more convenient alternative to the oral or the
injectable medication, the transdermal pen of maropitant may improve the management of both acute and chronic vomiting in cats. However, it is necessary that additional studies determine blood concentrations, bioavailability (with this base), and the duration of action in older cats and in cats with liver and renal deficiencies.

**Authors’ contributions**
Youcef Boukaache: conceptualization, investigation, methodology, software, supervision, writing-original draft, writing-review, and editing. Marie-Laurence Ferret: conceptualization, investigation, methodology, supervision, writing-review, and editing. Valérie Delteil-Prérotat: conceptualization, investigation, methodology, and supervision. Karim Khoukh: conceptualization, investigation, methodology, supervision, writing-review, and editing. Andra Enache: conceptualization, data curation, investigation, methodology, supervision, writing-review, and editing. Dorothee Iwaszkiw: investigation and resources. Sébastien Bertin: formal analysis, methodology, project administration, writing-review, and editing. Fabien Bruno: resources and validation.

**Conflict of interest**
The authors declare that there is no conflict of interest.

**Fig. 1.** Evolution of the number of vomiting before and after the administration of transdermal maropitant.
Funding
The study was financially supported by Pharmacie Delpech.

References


